Antengene's ATG-022 (CLDN18.2 ADC) Granted Breakthrough Therapy Designation for the Treatment of Gastric/Gastroesophageal Junction Adenocarcinoma ...Middle East

SHANGHAI and HONG KONG, Aug. 19, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for...

Hence then, the article about antengene s atg 022 cldn18 2 adc granted breakthrough therapy designation for the treatment of gastric gastroesophageal junction adenocarcinoma was published today ( Tuesday 19/08/2025 - 07:46 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Antengene's ATG-022 (CLDN18.2 ADC) Granted Breakthrough Therapy Designation for the Treatment of Gastric/Gastroesophageal Junction Adenocarcinoma )

Also on site :

• Crews respond to large fire at Denny Hamlin's parents' house in Stanley: Sources
• Reported tornado rips roofs off multiple homes in central Illinois
• Heidi Klum ditches bikini top to cozy up to husband Tom Kaulitz during St. Barths vacation